<DOC>
	<DOCNO>NCT00672022</DOCNO>
	<brief_summary>We want see Zavesca ( miglustat ) safe tolerated patient acute infantile onset GM2 gangliosidosis - classical Tay-Sachs infantile onset Sandhoff disease . We know miglustat inhibits formation GM2 ganglioside , compound store brain child Tay-Sachs Sandhoff disease . Since inhibits synthesis ganglioside , miglustat may able reduce delay onset clinical symptom .</brief_summary>
	<brief_title>Pharmacokinetics , Safety Tolerability Zavesca ( Miglustat ) Patients With Infantile Onset Gangliosidosis : Single Steady State Oral Doses</brief_title>
	<detailed_description>Specific Aims The primary objective study investigate pharmacokinetics ZAVESCAÂ® ( miglustat , OGT918 ) , give single dose steady state , infantile patient GM2 gangliosidosis . The secondary objective evaluate tolerability safety single multiple dos miglustat monitor disease progression use physical developmental assessment disease-specific biomarkers .</detailed_description>
	<mesh_term>Gangliosidoses</mesh_term>
	<mesh_term>Sandhoff Disease</mesh_term>
	<mesh_term>Gangliosidoses , GM2</mesh_term>
	<mesh_term>Tay-Sachs Disease</mesh_term>
	<mesh_term>Miglustat</mesh_term>
	<mesh_term>1-Deoxynojirimycin</mesh_term>
	<criteria>Inclusion criterion 1 . Diagnosis GM2 gangliosidosis , confirm demonstration profound deficiency hexosaminidase A A &amp; B peripheral blood leukocyte culture skin fibroblast , within previous 1 year nonbone marrow transplant recipient &lt; 2 year age , prior stem cell transplant stably engraft transplant patient &lt; 5 year age . 2 . Onset characteristic clinical symptom disease age 9 month . 3 . Normal renal hepatic function . 4 . Written inform consent parent legal guardian . Exclusion criteria 1 . Patients unable comply study procedure protocol , include refusal swallow food use mask taste study drug whose parent unwilling administer drug nasogastric gastrostomy tube . 2 . Patients receive investigational agent within 3 month study initiation . 3 . Patients anemic ( hemoglobin &lt; 11 g/dl , and/or hematocrit &lt; 34 % ) 4 . Patients history significant gastrointestinal disorder , include clinically significant diarrhea ( &gt; 3 liquid stool per day &gt; 7 day ) , without definable cause within 3 month baseline visit . 5 . Patients high probability die 6month assessment period study . 6 . Patients opinion investigator ( whatever reason ) think unsuitable study .</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>5 Years</maximum_age>
	<verification_date>July 2005</verification_date>
</DOC>